Cargando…

Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma

The high morbidity and mortality of hepatocellular carcinoma (HCC) has encouraged the search for new biomarkers to be used alongside alpha-foetoprotein (AFP) and imaging tests. The aim of this study was to evaluate the clinical contribution of protein induced by vitamin K absence or antagonist-II (P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Villalba-López, Francisco, Sáenz-Mateos, Luis Francisco, Sánchez-Lorencio, Maria Isabel, De La Orden-García, Virginia, Alconchel-Gago, Felipe, Cascales-Campos, Pedro Antonio, García-Bernardo, Carmen, Noguera-Velasco, José Antonio, Baroja-Mazo, Alberto, Ramírez-Romero, Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079651/ https://www.ncbi.nlm.nih.gov/pubmed/37024609 http://dx.doi.org/10.1038/s41598-023-32879-9

Ejemplares similares

Impact of PIVKA-II in diagnosis of hepatocellular carcinoma
por: Zakhary, Nadia I., et al.
Publicado: (2013)

Danger signals released during cold ischemia storage activate NLRP3 inflammasome in myeloid cells and influence early allograft function in liver transplantation
por: Lucas-Ruiz, Fernando, et al.
Publicado: (2022)

Selecting the Appropriate Downstaging and Bridging Therapies for Hepatocellular Carcinoma: What Is the Role of Transarterial Radioembolization? A Pooled Analysis
por: Lopez-Lopez, Victor, et al.
Publicado: (2023)

PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma
por: Tartaglione, Sara, et al.
Publicado: (2021)

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma
por: Kaneko, Shun, et al.
Publicado: (2022)

Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers
por: An, Shu, et al.
Publicado: (2023)

Changes and Clinical Significance of PIVKA-II in Hepatitis E Patients
por: Chen, Youran, et al.
Publicado: (2022)

Severe COVID-19 after liver transplantation, surviving the pitfalls of learning on-the-go: Three case reports
por: Alconchel, Felipe, et al.
Publicado: (2020)

Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data
por: Yu, Rentao, et al.
Publicado: (2017)

Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma
por: Park, Sang Joon, et al.
Publicado: (2017)

PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma
por: Feng, Honglei, et al.
Publicado: (2021)

The value of PIVKA-Ⅱ versus AFP for the diagnosis and detection of postoperative changes in hepatocellular carcinoma
por: Lee, Qiuyan, et al.
Publicado: (2021)

Performance evaluation of the Elecsys PIVKA‐II and Elecsys AFP assays for hepatocellular carcinoma diagnosis
por: Chan, Henry L Y, et al.
Publicado: (2022)

Clinical value of serum AFP and PIVKA‐II for diagnosis, treatment and prognosis of hepatocellular carcinoma
por: Tian, Shan, et al.
Publicado: (2022)

Primary colon cancer with a high serum PIVKA-II level
por: Kato, Kazuya, et al.
Publicado: (2014)

The Influence of Alcoholic Liver Disease on Serum PIVKA-II Levels in Patients without Hepatocellular Carcinoma
por: Kang, Keunhee, et al.
Publicado: (2015)

The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients
por: Xu, Fei, et al.
Publicado: (2021)

Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region
por: Kim, Do Young, et al.
Publicado: (2023)

The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma
por: Tran, Vinh Thanh, et al.
Publicado: (2023)

Modulating P2X7 Receptor Signaling during Rheumatoid Arthritis: New Therapeutic Approaches for Bisphosphonates
por: Baroja-Mazo, Alberto, et al.
Publicado: (2012)

Abnormal Prothrombin (PIVKA-II) Expression in Canine Tissues as an Indicator of Anticoagulant Poisoning
por: Maniscalco, Lorella, et al.
Publicado: (2021)

Tolerance in liver transplantation: Biomarkers and clinical relevance
por: Baroja-Mazo, Alberto, et al.
Publicado: (2016)

Utility of PIVKA-II and AFP in Differentiating Hepatocellular Carcinoma from Non-Malignant High-Risk Patients
por: Hadi, Hana, et al.
Publicado: (2022)

PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients
por: Suttichaimongkol, Tanita, et al.
Publicado: (2023)

Identification of the Best Cut-Off Value of PIVKA-II for the Surveillance of Patients at Risk of Hepatocellular Carcinoma Development
por: Caviglia, Gian Paolo, et al.
Publicado: (2023)

Emerging Role of NLRP3 Inflammasome and Pyroptosis in Liver Transplantation
por: Lucas-Ruiz, Fernando, et al.
Publicado: (2022)

Sex Differences between CRF1 Receptor Deficient Mice following Naloxone-Precipitated Morphine Withdrawal in a Conditioned Place Aversion Paradigm: Implication of HPA Axis
por: García-Carmona, Juan-Antonio, et al.
Publicado: (2015)

Transcriptional regulation by Poly(ADP-ribose) polymerase-1 during T cell activation
por: Saenz, Luis, et al.
Publicado: (2008)

Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma
por: Park, Hana, et al.
Publicado: (2013)

PIVKA-II level is correlated to development of portal vein tumor thrombus in patients with HBV-related hepatocellular carcinoma
por: Li, Tao, et al.
Publicado: (2019)

Value of AFP and PIVKA-II in diagnosis of HBV-related hepatocellular carcinoma and prediction of vascular invasion and tumor differentiation
por: Si, Yuan-Quan, et al.
Publicado: (2020)

The diagnostic value of PIVKA‐II, AFP, AFP‐L3, CEA, and their combinations in primary and metastatic hepatocellular carcinoma
por: Qi, Famei, et al.
Publicado: (2019)

The clinical application of PIVKA‐II in hepatocellular carcinoma and chronic liver diseases: A multi‐center study in China
por: Ji, Jun, et al.
Publicado: (2021)

PIVKA-II as a surrogate marker for prognosis in patients with localized hepatocellular carcinoma receiving stereotactic body radiotherapy
por: Cho, Ick Joon, et al.
Publicado: (2022)

Effect of PIVKA‐II and AFP secretion status on early recurrence of hepatocellular carcinoma after open and laparoscopic surgery
por: Cai, Yunshi, et al.
Publicado: (2023)

Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients
por: Ren, Tianying, et al.
Publicado: (2023)

Better performance of PIVKA-II for detecting hepatocellular carcinoma in patients with chronic liver disease with normal total bilirubin
por: Qian, Xiang-Jun, et al.
Publicado: (2023)

Soluble P2X7 Receptor Is Elevated in the Plasma of COVID-19 Patients and Correlates With Disease Severity
por: García-Villalba, Julio, et al.
Publicado: (2022)

P2X7 Receptor Activation Impairs Exogenous MHC Class I Oligopeptides Presentation in Antigen Presenting Cells
por: Baroja-Mazo, Alberto, et al.
Publicado: (2013)

Performance of Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) for Hepatocellular Carcinoma Screening in Chinese Population
por: Yu, Rentao, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_pftu1tlhg4fk2cin7rpi9gladq